Los Angeles Capital Management
ADVM

Los Angeles Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Los Angeles Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,138
Closed -$211K – 1520
2021
Q1 		$211K Sell
2,138
-1,845
-46% -$222K ﹤0.01% 1526
2020
Q4 		$432K Sell
3,983
-144
-3% -$17.8K ﹤0.01% 1261
2020
Q3 		$425K Sell
4,127
-1,045
-20% -$156K ﹤0.01% 1148
2020
Q2 		$1.08M Buy
5,172
+2,780
+116% +$492K 0.01% 815
2020
Q1 		$234K Buy
+2,392
New +$279K ﹤0.01% 1136

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Los Angeles Capital Management's ADVM Position: Q2 2021 in Review

Los Angeles Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 2,138 shares — an estimated $211K sold.

Los Angeles Capital Management first reported a position in ADVM in Q1 2020 and held it in 5 quarters. The position peaked at $1.08M in Q2 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Los Angeles Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 2,138 Adverum Biotechnologies shares in Q2 2021, an estimated $211K.
  • Los Angeles Capital Management first reported a position in Adverum Biotechnologies in Q1 2020 and held it in 5 quarters.
  • Los Angeles Capital Management's Adverum Biotechnologies position peaked at $1.08M in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Los Angeles Capital Management's 13F filing for Q2 2021, filed 5 Aug 2021.